Pharmacokinetic/pharmacodynamic analyses of plasma pathophysiology biomarkers in subjects with early Alzheimer's disease following lecanemab treatment

Documenti analoghi

• Amyloid Plaque Reduction as a Surrogate Marker of Efficacy: Assessment of Amyloid PET and Change in CDR‐SB Utilizing Semi‐Mechanistic Model
  di: Brian A. Willis, et al.
  Pubblicazione: (2024)
• Cerebrospinal fluid biomarker profiling of diverse pathophysiological domains in Alzheimer's disease
  di: Bianca A. Trombetta, et al.
  Pubblicazione: (2024)
• Understanding the impact of amyloid beta targeted therapies on biomarkers and clinical endpoints in Alzheimer's disease
  di: Ronald C. Petersen, et al.
  Pubblicazione: (2025)
• Leveraging recent advances in plasma biomarkers to optimize early proof of concept trials in Alzheimer's disease
  di: Garrett B. Duncan, et al.
  Pubblicazione: (2025)
• Tau biology, biomarkers, and therapeutics
  di: Bess Frost, et al.
  Pubblicazione: (2025)